Standard Family Office’s BioMarin Pharmaceuticals BMRN Stock Holding History

Standard Family Office’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10	Closed	-$1K	–	61
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	437
2022 Q2	$1K	Buy	+10	New	+$796	0.01%	190
2022 Q1	–	Sell	-18	Closed	-$2K	–	98
2021 Q4	$2K	Buy	+18	New	+$1.49K	0.02%	185
2021 Q1	–	Sell	-18	Closed	-$2K	–	623
2020 Q4	$2K	Buy	+18	New	+$1.43K	﹤0.01%	388

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Standard Family Office's BMRN Position: Q4 2022 in Review

Standard Family Office sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 10 shares — an estimated $1K sold.

Standard Family Office first reported a position in BMRN in Q4 2020 and held it in 4 quarters. The position peaked at $2K in Q4 2021. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Standard Family Office reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Standard Family Office sold 10 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $1K.
Standard Family Office first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Standard Family Office's BioMarin Pharmaceuticals position peaked at $2K in Q4 2021.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.